The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer

At present, the standard treatment approach for locally advanced cervical cancer is concurrent chemoradiotherapy (CCRT). An elevated pretreatment squamous cell carcinoma antigen (SCC Ag) level is associated with extensive tumors and poor survival for patients with cervical cancer treated with defini...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Jingxuan, Wang, Weiping, Wang, Yidan, Liu, Chengeng, Wang, Peichang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694518/
https://www.ncbi.nlm.nih.gov/pubmed/31416463
http://dx.doi.org/10.1186/s13014-019-1355-4
_version_ 1783443839771475968
author Fu, Jingxuan
Wang, Weiping
Wang, Yidan
Liu, Chengeng
Wang, Peichang
author_facet Fu, Jingxuan
Wang, Weiping
Wang, Yidan
Liu, Chengeng
Wang, Peichang
author_sort Fu, Jingxuan
collection PubMed
description At present, the standard treatment approach for locally advanced cervical cancer is concurrent chemoradiotherapy (CCRT). An elevated pretreatment squamous cell carcinoma antigen (SCC Ag) level is associated with extensive tumors and poor survival for patients with cervical cancer treated with definitive CCRT. SCC Ag levels can be used to help physicians make decisions regarding surgery, avoiding the complications of double treatment modalities. Elevated SCC Ag is associated with radiotherapy resistance, and the rate of SCC Ag reduction during CCRT can predict tumor response after treatment. Moreover, the failure of SCC Ag levels to normalize posttreatment can predict tumor relapse, with a specificity higher than 70%, and adjuvant therapies should be considered for these patients. SCC Ag also plays an important role in the early detection of tumor relapse in patients with cervical cancer during follow-up after CCRT, with high sensitivity and good cost-effectiveness.
format Online
Article
Text
id pubmed-6694518
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66945182019-08-19 The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer Fu, Jingxuan Wang, Weiping Wang, Yidan Liu, Chengeng Wang, Peichang Radiat Oncol Review At present, the standard treatment approach for locally advanced cervical cancer is concurrent chemoradiotherapy (CCRT). An elevated pretreatment squamous cell carcinoma antigen (SCC Ag) level is associated with extensive tumors and poor survival for patients with cervical cancer treated with definitive CCRT. SCC Ag levels can be used to help physicians make decisions regarding surgery, avoiding the complications of double treatment modalities. Elevated SCC Ag is associated with radiotherapy resistance, and the rate of SCC Ag reduction during CCRT can predict tumor response after treatment. Moreover, the failure of SCC Ag levels to normalize posttreatment can predict tumor relapse, with a specificity higher than 70%, and adjuvant therapies should be considered for these patients. SCC Ag also plays an important role in the early detection of tumor relapse in patients with cervical cancer during follow-up after CCRT, with high sensitivity and good cost-effectiveness. BioMed Central 2019-08-15 /pmc/articles/PMC6694518/ /pubmed/31416463 http://dx.doi.org/10.1186/s13014-019-1355-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Fu, Jingxuan
Wang, Weiping
Wang, Yidan
Liu, Chengeng
Wang, Peichang
The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer
title The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer
title_full The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer
title_fullStr The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer
title_full_unstemmed The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer
title_short The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer
title_sort role of squamous cell carcinoma antigen (scc ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694518/
https://www.ncbi.nlm.nih.gov/pubmed/31416463
http://dx.doi.org/10.1186/s13014-019-1355-4
work_keys_str_mv AT fujingxuan theroleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT wangweiping theroleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT wangyidan theroleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT liuchengeng theroleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT wangpeichang theroleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT fujingxuan roleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT wangweiping roleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT wangyidan roleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT liuchengeng roleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer
AT wangpeichang roleofsquamouscellcarcinomaantigensccaginoutcomepredictionafterconcurrentchemoradiotherapyandtreatmentdecisionsforpatientswithcervicalcancer

Ejemplares similares